Arrowhead showcases early obesity data; Instil bails on PD-1/VEGF drug

Arrowhead’s RNA drugs could aid with “high-quality” weight loss, according to one analyst. Elsewhere, the PD-1/VEGF field got less crowded and Amgen and Lilly struck startup deals.

By BioPharma Dive staff • Jan. 7, 2026

Alumis soars as TYK2 drug hits mark in psoriasis trials

Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral options for psoriasis, among them drugs from Takeda and Johnson & Johnson.

By Jonathan Gardner • Jan. 6, 2026

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.

By BioPharma Dive staff

Amgen buys protein-degrading startup Dark Blue for up to $840M

The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that could set it apart from current medications. 

By Gwendolyn Wu • Jan. 6, 2026

Moderna, searching for a rebound, to seek approval of mRNA flu shot

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead. 

By Delilah Alvarado • Jan. 5, 2026

Zenas shares crash after top drug misses expectations in immune disease study

While the company’s bispecific medication obexelimab met its objectives in a trial in IgG4-related disease, it didn’t appear to match the effectiveness of a recently approved Amgen drug.

By Jonathan Gardner • Jan. 5, 2026

Novo launches Wegovy pill; Argenx to swap CEOs

Novo Nordisk officially began marketing the pill version of its popular weight loss drug. Elsewhere, Sanofi bought a vaccine maker and an eczema therapy J&J acquired in a billion-dollar deal failed a key test. 

By Ben Fidler • Jan. 5, 2026

Biopharma CEO optimism is wavering in the US

The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.

By Kelly Bilodeau • Dec. 23, 2025

Trump to test ‘most favored nation’ pricing for Medicare; Shionogi pays $2.5B for ALS drug

Two pilot programs would tie Medicare costs and rebates in the U.S. to what’s paid in comparable countries. Elsewhere, AstraZeneca reported a setback and an “off the shelf” cell therapy showed promise.

By BioPharma Dive staff • Dec. 22, 2025

Radiopharmaceutical specialist Aktis seeks an IPO

The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound next year.

By Ben Fidler • Dec. 22, 2025

Cytokinetics set to battle Bristol Myers as FDA approves heart drug

The clearance is the first in Cytokinetics’ lengthy history and pits its drug Myqorzo against Bristol Myers’ Camzyos, which is on its way to topping $1 billion in sales this year.

By Ben Fidler • Dec. 21, 2025

BioMarin to buy rare disease drugmaker Amicus for $4.8B

Analysts said the deal makes sense for BioMarin, as it offers a late-stage clinical asset as well as two marketed therapies that generated nearly $450 million over the first nine months of this year.

By Jacob Bell • Dec. 19, 2025

Novo files for CagriSema approval; Merck and Pfizer’s trial win

Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.

By BioPharma Dive staff • Dec. 19, 2025

Galapagos TYK2 drug hits goal in one trial, misses in another

The Belgian biotech is still on the hunt for partners after reporting that its drug succeeded against an inflammatory skin and muscle disorder but missed in a lupus study.

By Jonathan Gardner • Dec. 19, 2025

Moderna gets funding for H5 pandemic influenza vaccine

The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government funding.

By Delilah Alvarado • Dec. 18, 2025

Takeda says $4B TYK2 drug succeeds in large psoriasis studies

The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to challenge Bristol Myers Squibb’s Sotyktu.

By Ben Fidler • Dec. 18, 2025

Orum, a biotech marrying ADCs with protein degraders, captures $100M in funding

The financing follows a strategic shift for Orum, which shelved its original lead program and is now pursuing a potential blood cancer treatment. 

By Gwendolyn Wu • Dec. 18, 2025

Peanut allergy patch succeeds in late-stage study 5 years after FDA rejection

DBV Technologies plans to use the latest Phase 3 results in a new submission to U.S. regulators in 2026.

By Kristin Jensen • Dec. 17, 2025

RA Capital backs drug for rare kind of chronic pain

The investment firm co-led a $125 million Series A round for Ambros Therapeutics, a Vivek Ramaswamy co-founded company with a medicine nearing pivotal testing.

By Jacob Bell • Dec. 17, 2025

Addition emerges with $100M to make gene therapies for chronic and rare diseases

Backed by a handful of prominent investors including the Gates Foundation, the startup is pursuing an approach it believes can sidestep issues seen with traditional gene therapy technology.

By Gwendolyn Wu • Dec. 17, 2025

Nektar sees silver lining as autoimmune drug ‘narrowly’ misses in alopecia study

Despite being unable to declare statistical success, the company claimed its therapy showed enough promise to support moving into late-stage testing. 

By Kristin Jensen • Dec. 16, 2025

FDA ‘proactively’ hands J&J a voucher; Pfizer issues 2026 forecasts

The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new cell therapy player emerged with $60 million in Series A funding.

By BioPharma Dive staff • Dec. 16, 2025

‘Zombie’ biotech buyer Xoma to acquire Generation Bio

The gene therapy developer has lost most of its value since going public in 2020 and saw a long road ahead for a delivery technology that had shown promise in preclinical tests.

By Gwendolyn Wu • Dec. 16, 2025

Argenx falters in effort to expand immune drug’s use

The company will stop two trials testing its blockbuster therapy Vyvgart in thyroid eye disease after treatment was judged to be ineffective at an interim checkpoint.

By Jonathan Gardner • Dec. 15, 2025

Sobi snaps up gout drug in $950M deal for startup Arthrosi

The deal revolves around a drug Sobi claimed could become the “therapy of choice” for people whose gout symptoms persist despite initial therapy. 

By Ben Fidler • Dec. 14, 2025

Arcus cancels work on Gilead-partnered cancer combo after trial setback

A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another blow to research on a once-promising target.

By Jonathan Gardner • Dec. 12, 2025